Dine Brands (DIN) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $0.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +33.33%. A quarter ago, it was expected that this parent company of Applebee's and IHOP restaurants would post earnings of $0.82 per share when it actually produced earnings of $0.73, delivering a surprise of -10.98%.Ove ...

分组1 - CeriBell, Inc. reported a quarterly loss of $0.36 per share, better than the Zacks Consensus Estimate of a loss of $0.43, representing an earnings surprise of +16.76% [1] - The company posted revenues of $24.78 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 4.40%, and compared to revenues of $18.53 million a year ago [2] - CeriBell, Inc. has surpassed consensus EPS estimates for four consecutive quarters [2] 分组2 - The stock has underperformed the market, losing about 8.9% since the beginning of the year, while the S&P 500 has declined by only 0.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.37 on revenues of $26.01 million, and for the current fiscal year, it is -$1.46 on revenues of $112.76 million [7] - The Zacks Industry Rank for Medical - Products is in the bottom 45% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

分组1 - AbCellera Biologics Inc. reported a quarterly loss of $0.03 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.18, representing an earnings surprise of +83.56% [1] - The company posted revenues of $44.85 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 565.48%, compared to revenues of $5.05 million a year ago [2] - Over the last four quarters, AbCellera has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed, losing about 11.4% since the beginning of the year, while the S&P 500 has declined by only 0.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.16 on revenues of $16.81 million, and -$0.67 on revenues of $57.07 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which AbCellera belongs, is currently in the top 37% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

分组1 - Alphatec reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, compared to a loss of $0.23 per share a year ago, representing an earnings surprise of +50.00% [1] - The company posted revenues of $212.93 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.13%, and this is an increase from year-ago revenues of $176.79 million [2] - Alphatec has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed, losing about 37.5% since the beginning of the year, while the S&P 500 has declined by only 0.1% [3] - The current consensus EPS estimate for the coming quarter is $0.01 on revenues of $201.28 million, and for the current fiscal year, it is $0.24 on revenues of $889.32 million [7] - The Medical - Instruments industry, to which Alphatec belongs, is currently in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Planet Fitness (PLNT) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.7 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.59%. A quarter ago, it was expected that this fitness center operator would post earnings of $0.72 per share when it actually produced earnings of $0.8, delivering a surprise of +11.11%.Over the last four quarters ...

分组1 - Interface reported quarterly earnings of $0.49 per share, exceeding the Zacks Consensus Estimate of $0.40 per share, and up from $0.34 per share a year ago, representing an earnings surprise of +22.50% [1] - The company achieved revenues of $349.39 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.27%, and an increase from $335.01 million year-over-year [2] - Interface has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has increased approximately 12.8% since the beginning of the year, while the S&P 500 has declined by 0.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $315 million, and for the current fiscal year, it is $2.00 on revenues of $1.44 billion [7] - The Zacks Industry Rank for Textile - Home Furnishing is in the bottom 29% of over 250 Zacks industries, indicating potential challenges for the sector [8]

分组1 - Claritev Corporation reported a quarterly loss of $4.88 per share, which was worse than the Zacks Consensus Estimate of a loss of $3.96, representing an earnings surprise of -23.23% [1] - The company posted revenues of $246.55 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 2.13%, and showing an increase from $232.15 million year-over-year [2] - Claritev Corporation has surpassed consensus revenue estimates four times over the last four quarters, but has only exceeded consensus EPS estimates once during the same period [2] 分组2 - The stock has underperformed significantly, losing about 45.6% since the beginning of the year, while the S&P 500 has gained 0.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.75 on revenues of $243.21 million, and for the current fiscal year, it is -$14.26 on revenues of $992.62 million [7] - The Medical Info Systems industry, to which Claritev Corporation belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

分组1 - Stepan Co. reported a quarterly loss of $0.02 per share, significantly missing the Zacks Consensus Estimate of $0.35, and compared to earnings of $0.12 per share a year ago, resulting in an earnings surprise of -105.71% [1] - The company posted revenues of $553.89 million for the quarter ended December 2025, which was 2% below the Zacks Consensus Estimate and an increase from $525.61 million year-over-year [2] - Stepan Co. shares have increased approximately 42% since the beginning of the year, outperforming the S&P 500's gain of 0.9% [3] 分组2 - The earnings outlook for Stepan Co. is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Stepan Co. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is $0.81 on revenues of $646.5 million, and for the current fiscal year, it is $3.62 on revenues of $2.52 billion [7] 分组3 - The outlook for the Chemical - Diversified industry, to which Stepan Co. belongs, is currently in the bottom 21% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Group 1 - Esab reported quarterly earnings of $1.35 per share, exceeding the Zacks Consensus Estimate of $1.34 per share, and up from $1.28 per share a year ago, representing an earnings surprise of +0.75% [1] - The company posted revenues of $687.6 million for the quarter ended December 2025, slightly missing the Zacks Consensus Estimate by 0.02%, but up from $633.2 million year-over-year [2] - Esab has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] Group 2 - The stock has gained approximately 16.9% since the beginning of the year, significantly outperforming the S&P 500, which has only gained 0.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.38 on revenues of $710.14 million, and for the current fiscal year, it is $5.81 on revenues of $2.92 billion [7] Group 3 - The Metal Products - Procurement and Fabrication industry, to which Esab belongs, is currently ranked in the top 7% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Esab was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6]

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -700.58%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.19 per share when it actually produced earnings of $0.2, delivering a surprise of +116.81%.Over the last four quarters ...